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OBJECTIVE—To identify, localize, and determine M1/M2 polar-
ization of epidydimal adipose tissue (eAT) macrophages (s)
during high-fat diet (HFD)-induced obesity.
RESEARCH DESIGN AND METHODS—Male C57BL/6 mice
were fed an HFD (60% fat kcal) or low-fat diet (LFD) (10% fat
kcal) for 8 or 12 weeks. eATMs (F4/80
 cells) were character-
ized by in vivo ﬂuorescent labeling, immunohistochemistry,
ﬂuorescence-activated cell sorting, and quantitative PCR.
RESULTS—Recruited interstitial macrophage galactose-type C-
type lectin (MGL)1
/CD11c
 and crown-like structure–associ-
ated MGL1
/CD11c
 and MGL1
med/CD11c
 eATMs were
identiﬁed after 8 weeks of HFD. MGL1
med/CD11c
 cells com-
prised 65% of CD11c
 eATMs. CD11c
 eATMs expressed a
mixed M1/M2 proﬁle, with some M1 transcripts upregulated
(IL-12p40 and IL-1), others downregulated (iNOS, caspase-1,
MCP-1, and CD86), and multiple M2 and matrix remodeling
transcripts upregulated (arginase-1, IL-1Ra, MMP-12, ADAM8,
VEGF, and Clec-7a). At HFD week 12, each eATM subtype
displayed an enhanced M2 phenotype as compared with HFD
week 8. CD11c
 subtypes downregulated IL-1 and genes medi-
ating antigen presentation (I-a, CD80) and upregulated the M2
hallmark Ym-1 and genes promoting oxidative metabolism (PGC-
1) and adipogenesis (MMP-2). MGL1
med/CD11c
 eATMs up-
regulated additional M2 genes (IL-13, SPHK1, CD163, LYVE-1,
and PPAR-). MGL1
med/CD11c
 ATMs expressing elevated
PGC-1, PPAR-, and Ym-1 transcripts were selectively enriched
in eAT of obese mice fed pioglitazone for 6 days, conﬁrming the
M2 features of the MGL1
med/CD11c
 eATM transcriptional
proﬁle and implicating PPAR activation in its elicitation.
CONCLUSIONS—These results 1) redeﬁne the phenotypic po-
tential of CD11c
 eATMs and 2) suggest previously unappre-
ciated phenotypic and functional commonality between murine
and human ATMs in the development of obesity and its
complications. Diabetes 59:1171–1181, 2010
C
hronic inﬂammation is a pathogenic factor in
obesity complications, in particular insulin re-
sistance (1,2). A signiﬁcant advance in our un-
derstanding of obesity-associated inﬂammation
and insulin resistance has been recognition of the under-
lying role of adipose tissue macrophages (ATMs) (1–4).
Tissue Ms are phenotypically heterogeneous and are
broadly characterized according to activation (polariza-
tion) state by the M1/M2 classiﬁcation system (5,6): Clas-
sical M1 activation induced by interferon- and
lipopolysaccharide (LPS) deﬁnes proinﬂammatory, micro-
bicidal Ms. M1 Ms are the ﬁrst line of defense against
intracellular pathogens, and they prime toward a Th1
adaptive immune response by producing interleukin
(IL)-12 (7). In contrast, Ms expressing one of several
overlapping M2 polarization states are activated by IL-4/
IL-13 (M2a or “alternative” activation), diverse stimuli
(e.g., apoptotic cells) in concert with LPS (M2b), or IL-10,
transforming growth factor (TGF)-, or glucocorticoids
(M2c). M2-polarized M function in tissue remodeling
during development and in response to injury, and they
promote the resolution of acute inﬂammation. Although
M2a polarized Ms are also involved in antiparasite de-
fense and Th2 priming, it has been suggested that the
predominant role of M2-polarized Ms is the regulation of
tissue homeostasis (8,9). Thus, M2-polarized Ms typically
upregulate arginase (ARG)-1 and downregulate inducible
nitric oxide sythase (iNOS) (thereby promoting collagen
production at the expense of microbicidal NO); elevate the
expression of inﬂammation-suppressive factors (IL-10 and
IL-1Ra), matrix metalloproteinases (MMPs), and proangio-
genic mediators; and express an overall attenuated proin-
ﬂammatory and Th1-priming gene expression proﬁle.
Our current understanding of how ATMs promote
obesity-associated inﬂammation and insulin resistance is
based in large part on the “phenotype switch” model of
Lumeng et al. (10). In this model, obesity promotes the
recruitment of M1-polarized ATMs that shift the nonin-
ﬂammatory milieu maintained by M2a polarized, resident
ATMs toward a proinﬂammatory state. In epididymal AT
(eAT), these M1 ATMs (eATMs) are distinguished by 1)
localization to crown-like structures (CLS) and cell “clus-
ters” of active remodeling around dead adipocytes
(7,11,12), 2) elevated expression of the CC chemokine
receptor CCR2 and the dendritic cell marker CD11c in
conjunction with downregulation of the signature M2
lectin macrophage galactose-type C-type lectin (MGL)1
(11), and 3) by an M1 gene expression proﬁle featuring
upregulated iNOS and downregulated ARG-1 (10,11,13).
The M1 polarization of eATMs is in certain respects
counterintuitive. Adipose tissue expansion is a process of
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moval of apoptotic cells (adipocytes), extracellular matrix
remodeling, angiogenesis, and new adipogenesis (12,14–
16). In other tissues, these types of remodeling and repar-
ative processes typically involve M2-polarized Ms (5,6).
Moreover, these features of adipose tissue remodeling are
manifest in or near the “clusters” to which CCR2
 and/or
CD11c
 eATMs selectively localize, and roles for cluster-
associated eATMs in adipocyte clearance and angiogen-
esis have been proposed (7,12,14). In humans, fat mass
expansion is associated with the accumulation of anti-
inﬂammatory or mixed M1/M2-polarized ATMs (17).
These ATMs exhibit “remodeling” phenotypes (18) char-
acterized by increased MMP activities and elevated ex-
pression of lymphatic vessel endothelial hyaluronan
receptor (LYVE)-1, a mediator of adipose tissue angiogen-
esis (19). Considered together, these observations suggest
that one or more populations of recruited eATMs are
likely to express features of an M2-like remodeling pheno-
type during the development of murine obesity and insulin
resistance.
Here we identify, localize, and transcriptionally charac-
terize eATM subtypes in mice fed a high-fat diet (HFD)
for 8 or 12 weeks, a period of progressively increasing
body weight, eAT remodeling, eATM recruitment, and
whole-body insulin resistance (12). Our observations re-
deﬁne the phenotypic potential of CD11c
 eATMs and
suggest that obesity and insulin resistance develop in this
model in association with a coincident M2 and M1 pheno-
typic progression.
RESEARCH DESIGN AND METHODS
Animals and diets. Six-week-old male C57BL/6j mice were fed a low-fat diet
(LFD) (10% energy from fat) or an HFD (60% energy from fat) (12) for 8, 10,
or 12 weeks at The Jackson Laboratory (Bar Harbor, ME). Following
overnight shipment, mice were fed the same diets in a viral pathogen–free
facility for 2–3 days before use. Mice fed an HFD for 10 weeks were
maintained for an additional 6 days at the Human Nutrition Research Center
on Aging on either an HFD or an HFD containing (0.01%, wt/wt) pioglitazone
(PIO) (HFDPIO). Six-week-old standard diet–fed mice were maintained for
an additional 4 weeks on standard diet or HFD following in vivo phagocyte
labeling with PKH26 (see below). Mice were killed by CO2/cervical disloca-
tion, and eAT was processed as described below. All procedures adhered to
Human Nutrition Research Center on Aging Institutional Animal Care and Use
Committee Guidelines.
Intraperitoneal insulin tolerance test (ITT). Whole-body insulin resis-
tance was determined in mice as described (12).
Immunohistochemistry and immunoﬂuorescence. Parafﬁn sections were
probed with goat anti-mouse MGL1 (R&D Systems, Minneapolis, MN) or with
IgG isotype control followed by horseradish peroxidase–conjugated second
antibody (12). For immunoﬂuorescence, eAT was ﬁxed in zinc-paraformalde-
hyde (Zn-PFA) (20), minced into 1  1  1 mm pieces, blocked with horse
serum, and incubated with MGL1 antibody in PBS/horse serum (o/n, 4°C)
followed by DyLight488-conjugated secondary antibody and Hoechst reagent.
Stromal vascular cell isolation. eAT was placed into Krebs-Henseleit buffer
(21) supplemented with 4% fatty acid–free BSA, 5 mmol/l D-glucose, and 200
nmol/l PIA; minced; centrifuged (500g, 5 min, room temperature); digested
(30–40 min, 37°C) with endotoxin-free Liberase 3 (0.3 units/ml, Roche Applied
Science, Indianapolis, IN) containing 50 units of DNase I (Sigma-Aldrich);
passed through a sterile 100-	m strainer (Fischer Scientiﬁc, Franklin, MA);
and centrifuged (500g, 5 min, room temperature). Following incubation with
erythrocyte lysis buffer, stromal vascular cells (SVCs) were resuspended (1 
10
6 cells/100 	l) in cold ﬂuorescence-activated cell sorting (FACS) buffer (PBS
containing 1 mmol/l EDTA, 25 mmol/l HEPES, and 1% [wt/vol] fatty acid–free
BSA) until immunolabeling.
Flow cytometry and SVC sorting. SVCs were incubated on ice (10 min) with
FcBlock (5 	g/ml) (BD Pharmingen, San Jose, CA), followed by incubation
with ﬂuorophore-conjugated antibodies or isotype controls. Antibodies in-
cluded phycoerythrin-Cy5–conjugated F4/80 (eBioscience, San Diego, CA),
phycoerythrin-conjugated CD11c (BD Pharmingen, Franklin Lakes, NJ), goat
anti-mouse MGL1 (R&D Systems), and donkey anti-goat DyLight488 (Jackson
ImmunoResearch Laboratories, West Grove, PA). Cells were analyzed using a
FACScalibur ﬂow cytometer equipped with CellQuest software (Becton
Dickinson, San Jose, CA) or sorted on a MoFlo multilaser system sorter
(Beckman Coulter, Brea, CA) using Summit software (Beckman Coulter).
Gating and compensation strategies are depicted in Fig. 1 and supplemental
Fig. 1 (available at http://diabetes.diabetesjournals.org/cgi/content/full/db09-
1402/DC1). Sorted ATMs were collected in buffer containing RNase inhibitor
and stored at 70°C.
PKH26 labeling of adipose tissue phagocytes. Six-week-old standard
diet–fed mice were injected (intraperitoneally) with 200 	lo f0 . 5	mol/l
PKH26 (Sigma-Aldrich, St. Louis, MO). Four days later, mice were assigned to
either standard diet or HFD cohorts for 4 weeks, after which ATMsi ne A T
were analyzed by FACS.
Quantitative PCR. RNA was extracted using RNeasy Mini and RNeasy
MinElute Cleanup kits (Qiagen) and reverse transcribed and ampliﬁed using
the WT-Ovation RNA Ampliﬁcation System (NuGEN Technologies, San Car-
los, CA). Quantitative PCR was conducted using SYBR Green (Applied
Biosystems) (12). Fold differences in gene expression were calculated as
2


Ct using cyclophilin A as the housekeeping gene. Primer sequences are in
supplemental Table 1.
Statistics. Data are expressed as means  SE. Means were compared by t
test or by ANOVA or GLM procedures in conjunction with Tukey honestly
signiﬁcant difference test (SAS version 9.1). Signiﬁcance was set at P  0.05.
RESULTS
CD11c
 ATMs with differential MGL1 expression
levels are recruited to and accumulate in eAT of mice
fed an HFD. As reported (12) feeding the HFD for 8 weeks
increased body and eAT weights and induced whole-body
insulin resistance (Table 1). Although total SVCs increased
in response to HFD, SVCs per gram eAT did not (Table 1).
Flow cytometry (Fig. 1A) conﬁrmed that the preponder-
ance (90%) of eATMs (F4/80
 cells) in mice fed a LFD
did not express CD11c and that the HFD induced the
accumulation of CD11c
 eATMs (10). Overall, there
appeared to be a continuum of MGL1 expression rather
than distinct populations of MGL1-expressing cells (Fig.
1A and C). When gated for MGL1, CD11c
 eATMs
unexpectedly exhibited a broad distribution of MGL1
staining intensity that partially overlapped that of MGL1
/
CD11c
 cells (Fig. 1A, bottom panel). The overlapping and
nonoverlapping cells were deﬁned as MGL1
med/CD11c

and MGL1
/CD11c
, respectively, based on staining inten-
sity (Fig. 1A and 1B) and transcript levels (Fig. 1C and
supplemental Table 2). When only CD11c
 cells were
considered, cells designated as MGL1
med/CD11c
 ex-
pressed three times the level of MGL1 mRNA than cells
designated MGL1
/CD11c
 (P 
 0.001). Surprisingly,
MGL1
med/CD11c
 eATMs comprised the majority of
CD11c
 cells (Fig. 1D). In vivo pulse experiments with the
phagocyte-labeling dye PKH26 (Fig. 1E) suggest that sim-
ilar to MGL1
/CD11c
 cells (Fig. 1E and 11), MGL1
med/
CD11c
 ATMs are recruited to eAT (i.e., are not derived
from resident MGL1
/CD11c
 cells present at the initia-
tion of HFD). PKH26 labeling (Fig. 1E) also revealed
HFD-induced recruitment of new (PKH26-negative)
MGL1
/CD11c
 eATMs.
CD11c
 eATMs are the predominant component of
CLS and cell clusters surrounding dead adipocytes (11).
Immunoﬂuorescent staining of whole eAT labeled numer-
ous MGL1-expressing cells within such clusters (Fig. 2A,
bottom left panel), consistent with the presence of
MGL1
med/CD11c
 eATMs (Fig. 1). As previously re-
ported (11), some cell clusters were composed predomi-
nantly of MGL1
 eATMs (Fig. 2A, bottom right panel).
Immunohistochemistry revealed MGL1-expressing cells
within CLS (Fig. 2B, left panel) and in areas of active
remodeling around dead adipocytes (Fig. 2B, right panel).
These results suggest that MGL1
med/CD11c
 eATMs are
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FIG. 1. CD11c
 eATMs exhibiting differential MGL1 expression (MGL1
med/CD11c
 and MGL1
/CD11c
) accumulate in the eAT of mice fed an
HFD. SVCs were obtained by collagenase digestion from eAT of mice fed an HFD or LFD for 8 weeks, labeled with F4/80, MGL1, and CD11c
antibodies and analyzed by ﬂow cytometry. A: HFD-associated increase in F4/80
/CD11c
 eATMs reﬂects increases in two ATM subtypes,
designated MGL1
med/CD11c
 (R2) and MGL1
/CD11c
 (R1) according to their MGL1 staining intensity. B: Conﬁrmation of MGL1 protein
expression in MGL1
/CD11c
 and MGL1
med/CD11c
 eATMs by ﬂuorescence microscopy of sorted eATMs (as in A). C: Gene expression for
F4/80, MGL1, and CD11c in sorted eATM subtypes. D: Quantiﬁcation of eATM subtypes in response to 8 and 12 weeks of HFD demonstrating
the absolute and proportional increase in CD11c
 and CD11c
 subtypes during the HFD time course. *P < 0.05; **P < 0.01, ANOVA and Tukey
test. E: Evidence that MGL1
med/CD11c
 eATMs are recruited rather than derived by phenotypic progression from resident MGL1
/CD11c
 cells.
Lean mice were pulsed with the phagocyte-speciﬁc dye PKH26 and subsequently fed 2 standard diet or an HFD for 1 month followed by FACS of
eATMs. Only ATMs present in eAT before clearance of the dye (24 h) express the label. (A high-quality digital representation of this ﬁgure
is available in the online issue.)
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surrounding moribund adipocytes.
eATMs express mixed M1/M2 transcriptional pro-
ﬁles after 8 weeks of HFD. As expected, interstitial
MGL1
/CD11c
 eATMs in mice fed an LFD displayed
elevated levels of canonical M2 transcripts (IL-13, IL-10,
Ym-1, sphingosine kinase 1 [SPHK1], signal transducer and
activator of transcription [STAT]-6, CD206 [mannose re-
ceptor], and CD163 [hemoglobin scavenger receptor]) and
relatively reduced levels of M1 transcripts (IL-12p40 and
IL-1) (Table 2; quantitative data summarized in Table 2
are presented in supplemental Fig. 2). In contrast, MGL1
/
CD11c
 eATMs at HFD week 8 expressed elevated levels
of CCR2 and several hallmark M1 transcripts (iNOS and
IL-12p40), coincident with reduced expression of some M2
transcripts (IL-13, SPHK1, CD206, and CD163) and in-
creases in M2 genes with inﬂammation-suppressive func-
tions (IL-10, IL-1Ra, and STAT-6) (Table 2). These results
indicate that the HFD recruits new interstitial MGL1
/
CD11c
 eATMs (Fig. 1E) that express enhanced M1 and
altered M2 transcriptional proﬁles.
Notably, neither CD11c
 eATM subtype expressed an
overall M1-polarized phenotype after 8 weeks of HFD.
Most surprisingly, ARG-1 expression was upregulated and
iNOS expression was dramatically attenuated in CD11c

eATMs as compared with interstitial MGL1
/CD11c

eATMs (Table 2). CD11c
 eATMs also upregulated
genes promoting tissue remodeling, including MMP-12
(22), and a proteinase with a disintegrin and metallopro-
teinase domain (ADAM)-8, a mediator of Th2-dependent
airway remodeling in asthma (23). CD11c
 eATMs also
expressed relatively high levels of vascular endothelial
growth factor (VEGF), and the MGL1
/CD11c
 subtype
expressed more TGF-1 mRNA (Table 2). These remodel-
ing signatures were associated with an M2-like expression
pattern of several genes, including the upregulation of
IL-1Ra interleukin-1 receptor antagonist and the down-
regulation of the M1-associated genes MCP-1 monocyte
chemoatractant protein, caspase-1, and toll-like receptor
(TLR)-4.
Both CD11c
 subtypes also expressed relatively greater
amounts of M1 transcripts with proinﬂammatory (IL-1)
and Th1-priming (IL-12p40) functions, and they downregu-
lated several inﬂammation-suppressive (M2) genes (IL-10,
IL-13, and STAT6) and the prototypic M2 markers Ym-1
CD206 and CD163 (Table 2). These data are consistent
with the reported M1 polarization of MGL1
 and CD11c

eATMs (10,11,24). However, expression of tumor necro-
sis factor- and IL-6 were comparable in CD11c
 and
CD11c
 eATMs (data not shown), perhaps reﬂecting the
induction of these genes in CD11c
 ATMs by the colla-
genase procedure (25). In summary, CD11c
 eATMsi n
mice fed an HFD for 8 weeks express mixed M1 (proin-
ﬂammatory) and M2 (remodeling) transcriptional proﬁles.
Levels of M1 and M2 transcripts in MGL1
med/CD11c

eATMs were intermediate between those measured in
MGL1
/CD11c
 and MGL1
/CD11c
 eATMs, respec-
tively (Table 2 and supplemental Fig. 2). When only gene
expression data for HFD-fed mice were compared, tran-
script levels of 17 of 34 genes were signiﬁcantly different in
MGL1
med/CD11c
 eATMs as compared with MGL1
/
CD11c
 eATMs (supplemental Table 2). These observa-
tions support the viewpoint that MGL1
med/CD11c

eATMs are a distinct subtype with an intermediate
phenotype consistent with the expression of both MGL1
and CD11c.
Prolonged HFD feeding promotes distinctive pat-
terns of altered gene expression in MGL1-expressing
and CD11c-expressing eATMs. As reported (12), 12
weeks of HFD induced weight gain, eAT remodeling
(manifest as reduced eAT mass coincident with increased
SVCs), and exacerbated whole-body insulin resistance
(Table 1). Each of the three eATM subtypes increased in
number (per gram eAT) (Fig. 1D, upper panel), but the
proportion of eATMs that were MGL1
/CD11c
 actually
decreased (Fig. 1D, bottom panel). Of note, MGL1
med/
CD11c
 eATMs remained the predominant CD11c

eATM subtype (Fig. 1D). At HFD week 12 eATMs
exhibited global changes in the expression of genes in-
volved in inﬂammation, antigen presentation, tissue re-
modeling, and metabolism consistent with increased M2
polarization, especially in the two MGL1-expressing sub-
types (supplemental Fig. 3). The direction and magnitude
of these changes are summarized in Fig. 3. MGL1
/
CD11c
 and MGL1
med/CD11c
 eATMs upregulated hall-
mark M2 genes (IL-13, Ym-1, SPHK1, and TGF-1),
downregulated iNOS, and upregulated the adipogenic met-
alloproteinase MMP-2 (26) (Fig. 3). MGL1
med/CD11c

eATMs selectively upregulated LYVE-1 (19,27) while
maintaining relatively high levels of VEGF and MMP-12
(Fig. 3). When compared with benchmark M2-polarized
(MGL1
/CD11c
) eATMs from mice fed an LFD (Table
3), MGL1-expressing eATMs in mice fed an HFD for 12
weeks had comparable or a more pronounced M2-like
expression proﬁle of genes regulating inﬂammation, lipid
metabolism, tissue remodeling, and antigen presentation.
However, they continued to express M1-like levels of
CD163, CD206, SPHK1 (reduced), and IL-12p40 (in-
creased) as compared with M2-polarized eATMs from
mice fed an LFD (Table 3).
Feeding the HFD for 12 weeks robustly upregulated the
transcriptional coactivator peroxisome proliferator–acti-
vated receptor (PPAR)- coactivator (PGC)-1 in both
CD11c
 eATM subtypes (Fig. 3), suggesting enhanced
oxidative (i.e., M2-associated) metabolism (28). At this
time, mRNA levels of both PGC-1 and PPAR- (but
neither PPAR- nor PPAR-) were three- to ﬁvefold greater
TABLE 1
Body and eAT weights, SVC numbers in eAT, and whole-body insulin resistance (ITT) in mice fed either the LFD or HFD for 8 (n 

6) or 12 (n 
 7–11) weeks
Body weight
(g)
eAT weight
(g)
Total number of
SVCs (10
6)
Area under curve
(ITT)
8 weeks LFD 28.27  0.33* 0.54  0.02* 1.23  0.13* 5,200  260*
8 weeks HFD 37.65  0.56† 2.24  0.19† 4.78  0.31† 6,760  315†
12 weeks LFD 29.21  0.61* 0.63  0.06* 1.99  0.26* —
12 weeks HFD 40.95  0.61‡ 1.86  0.10† 8.00  0.71‡ 7,890  346‡
Data are means  SE. Means identiﬁed by different symbols are signiﬁcantly different (P  0.05, ANOVA and Tukey procedure).
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med/CD11c
 eATMs than in the other two
eATM subtypes (P  0.05) (supplemental Fig. 4).
CD11c
 eATMs expressed relatively less IL-1 and genes
involved in antigen presentation (I-a, CD80, and CD86)
(Fig. 3). Overall, these results demonstrate M2-like
changes in lipid/oxidative metabolism and inﬂammatory
gene expression in CD11c
 eATMs between weeks 8 and
12 of HFD. Importantly, when compared with benchmark
M2-polarized eATMs (Table 3), CD11c
 eATMso fm i c e
fed an HFD for 12 weeks expressed comparable or greater
levels of multiple M2-associated transcripts (STAT6, IL1-
Ra, C type lectin [Clec]-7a, Arg-1, PGC-1, TGF, MMP-2,
MMP-12, VEGF, and ADAM-8) and equivalent or reduced
levels of several M1-associated transcripts (iNOS, CD80,
and CD86). These observations underscore the M2/remod-
eling features of the CD11c
 eATM transcriptional pro-
ﬁle during HFD-induced obesity.
MGL1
med/CD11c
 ATMs preferentially accumulate
in eAT of obese mice fed PIO. As both PGC-1 and
PPAR- are targets of PPAR-, it was plausible that the
M2-like gene expression changes observed in MGL1
med/
CD11c
 eATMs between weeks 8 and 12 of HFD (Fig. 3)
reﬂected increased PPAR- activation (29). Accordingly,
we phenotyped eATMs from mice maintained on HFD
for 10 weeks and then fed either HFD or HFD containing
the PPAR-/- agonist PIO (HFDPIO) for an additional 6
days. PIO treatment signiﬁcantly ameliorated hyperinsu-
linemia and upregulated uncoupling protein-1 in eAT (Fig.
4), conﬁrming PPAR- activation. Coincidentally, mRNA
levels of both F4/80 and MGL1 were increased in mice fed
40 mm 50 mm
Isotype control Isotype control + Hoechst
MGL1 Ab + Hoechst MGL1 Ab + Hoechst
A
B
FIG. 2. MGL1-expressing eATMs are associated with CLS and contiguous remodeling areas in eAT. A: MGL1 immunostaining was performed on
eAT whole mounts from mice fed an HFD and examined by ﬂuorescence microscopy. Lower left panel: MGL1-expressing cells (green) were
localized to clusters (arrow) and interstitium (arrowheads). Right lower panel: An example of an MGL1-negative cluster. Blue color (Hoechst’s
reagent) identiﬁes nuclei of MGL1
 cells. B: MGL1 immunostaining of parafﬁn-embedded sections from mice fed an HFD. MGL1
 cells are seen
associated with MGL1
 cells in CLS (left panel) and in associated remodeling areas (right panel, arrowheads). (A high-quality digital
representation of this ﬁgure is available in the online issue.)
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M2-polarized eATMs. Unexpectedly, CD11c mRNA levels
also increased (Fig. 4). Flow cytometry revealed a selec-
tive increase in MGL1
med/CD11c
 eATMs in mice fed
HFDPIO, resulting in a signiﬁcant increase in the pro-
portion of CD11c
 cells expressing MGL1 (Fig. 4). These
results suggest that MGL1
med/CD11c
 ATMs are prefer-
entially recruited and/or accumulate in eAT of HFD-fed
mice in response to short-term systemic PPAR- agonism.
Importantly, MGL1
med/CD11c
 eATMs from mice fed
HFDPIO displayed elevated levels of Ym-1, PGC-1, and
PPAR- (but not PPAR-) mRNAs (Fig. 4). This pattern of
M2-associated gene expressions mirrors in part that ob-
served in MGL1
med/CD11c
 eATMs from mice fed HFD
for 12 weeks (Fig. 3 and supplemental Fig. 4).
Mixed M1/M2 remodeling transcriptional proﬁle in
whole eAT during HFD-induced obesity. Finally, we
determined a mixed M1/M2 and remodeling transcriptional
proﬁle at the tissue level during HFD-induced obesity.
Quantitative PCR of selected eAT transcripts indicated
that the expression of M2/remodeling genes MGL1, IL-10,
IL-13, TGF-1, ADAM-8, and MMP-2 increased progres-
sively in eAT during the course of HFD (Fig. 5). MMP12
mRNA (induced 300-fold in CD11c
 eATMs) (Table 3)
was upregulated 100- and 150-fold in eAT at HFD weeks
8 and 12, respectively (data not shown). As expected,
transcript levels of M1 cytokines (IL-12p40, IL-1, and
tumor necrosis factor-) also increased during the HFD
time course, but iNOS mRNA levels decreased at week 12
(Fig. 5), consistent with downregulation in eATMs (Ta-
ble 3 and supplemental Fig. 3). Overall, these data demon-
strate progressive, coordinate increases in the expression
of both M2/remodeling and M1-associated genes in eAT
during the course of HFD-induced obesity and insulin
resistance (Table 1).
DISCUSSION
Employing an established model of HFD-induced obesity
(12), we demonstrate that eATMs recruited in response
to HFD express mixed M1/M2 and remodeling transcrip-
tional proﬁles and that these proﬁles become more M2-like
with extended HFD feeding. Human ATMs have recently
been shown to express mixed M1/M2 remodeling pheno-
types (17,18), thus distinguishing them from the M1-
polarized eATMs reported for obese mice (11,24). By
demonstrating the pleiotropic transcriptional proﬁles of
eATMs in murine obesity, the present study suggests
previously unappreciated phenotypic and functional com-
monality between murine and human ATMs in the devel-
opment of obesity and its complications.
We identiﬁed three subtypes of recruited eATMsi n
mice fed an HFD, including the MGL1
/CD11c
 and
MGL1
/CD11c
 eATMs that were previously reported to
be M2a and M1 polarized, respectively (11). In contrast to
a recent report (30), our sorting strategy did not identify
CD11c
 and CD11c
 eATMs as F4/80
lo and F4/80
hi,
respectively (Fig. 1A and C). As expected, interstitial
MGL1
/CD11c
 eATMs were M2 polarized in mice fed
an LFD (Table 2). HFD induced the recruitment of MGL1
/
CD11c
 eATMs expressing an altered M2 transcriptional
proﬁle and elevated levels of several M1 transcripts (Table
2). These recruitment data, obtained in young, lean
PKH26-injected mice subsequently fed an HFD differ from
results of a prior study (11) that reported little or no
recruitment of interstitial (MGL1
) eATMs in older,
obese HFD-fed mice injected with PKH26.
HFD did not elicit classical M1 polarization in MGL1
/
CD11c
 eATMs but rather a mixed M1/M2-like pattern of
gene expression characterized by enhanced expression of
IL-12p40 and IL-1 (M1) coincident with downregulated
expression of iNOS and caspase-1 and upregulated IL-1Ra
(M2). Moreover, MGL1
/CD11c
 eATMs upregulated
transcripts involved in matrix remodeling and angiogene-
sis (ARG-1, ADAM-8, MMP-12, VEGF, and TGF-1). During
the preparation of this manuscript, Fujisaka et al. (31)
reported high levels of ARG-1 gene expression in CD11c

eATMs in mice fed an HFD for 17 weeks. Our results
extend this observation and suggest that MGL1
/CD11c

eATMs in the present study express a mixed M1/M2
remodeling phenotype.
Surprisingly, cluster-associated eATMs expressing
both MGL1 and CD11c (i.e., MGL1
med/CD11c
) constituted
the majority (65–70%) of CD11c
 eATMs (and 50% of
CD11c
 eATMs after 20 weeks of HFD [not shown]).
While this manuscript was in review, Westcott et al. (32)
reported the unanticipated observation of substantially
reduced numbers of CD11c
 eATMsi nM G L 1
/ mice
fed an HFD, thereby supporting our observation of the
TABLE 2
Mixed M1/M2 remodeling transcriptional proﬁles in CD11c

eATMs at HFD week 8
Gene
LFD HFD HFD HFD
MGL1
/
CD11c

MGL1
/
CD11c

MGL1
med/
CD11c

MGL1
/
CD11c

M2
ARG-1 * * 1*† 1†
IL-1Ra * 1† 1‡ 1‡
TGF1* † 2*† 2*† 1*
PGC-1 * 1* 1* 1*
ADAM-8 * 1† 1‡ 1§
MMP-12 * 1* 1† 1†
VEGF * 1* 1† 1‡
Clec7a * * 1* 1*
IL-10 *† 1* 2† 2‡
IL-13 * 2*† 2*† 2†
Ym-1 * * 2* 2*
STAT-6 * 1* * *
SPHK1 * 2† 2† 2†
CD163 * 2† 2‡ 2‡
CD206 * 2† 2‡ 2‡
MMP-2 * 2*† 2† 2†
M1
iNOS *† 1† 2* 2*
IL-1 * * 1† 1†
IL12p40 * 1*† 1† 1†
I-a *† 2* 1† 1‡
CCR2 * 1† 1†‡ 1‡
MCP-1 * 2† 2‡ 2‡
Caspase-
1* † * 2† 2*†
TLR4 * * 2† 2†
CD86 * 2† 2‡ 2‡
CD80 * * * *
STAT-1 * * * *
2 and 1 arrows indicate reduced or increased gene expression,
respectively, as compared with MGL1
/CD11c
 eATMs from LFD-
fed mice (n 
 6) (see online appendix Fig. 2 for quantitative data
summarized in this table). Transcript levels designated by different
symbols are signiﬁcantly different (P  0.05, ANOVA and Tukey
procedure).
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 eATMsi n
the present study (Fig. 1). Occasional eATMs expressing
both MGL1 and CD11c were previously identiﬁed next to
clusters (11), but the phenotype of these eATMs was
undetermined. MGL1
med/CD11c
 eATMs express a
mixed M1/M2 phenotype with transcript levels intermedi-
ate between MGL1
/CD11c
 and MGL1
/CD11c

eATMs. This intermediate phenotype raised the possibil-
ity that MGL1
med/CD11c
 eATMs were derived from
interstitial MGL1
/CD11c
 cells. Lipid scavenging, a key
function of eATMs in obesity (7), promotes CD11c
expression in Ms (33) and could conceivably promote
the phenotypic progression of CD11c
 eATMst oa
CD11c
 phenotype. However, the almost total absence of
PKH26 dye among MGL1
med/CD11c
 eATMs argues
against their phenotypic progression from resident
MGL1
/CD11c
 eATMs (Fig. 1E). Irrespective of origins,
the phenotype of MGL1
med/CD11c
 eATMs is likely to
reﬂect exposure to two sets of adipose tissue microenvi-
ronmental cues (e.g., cytokines, lipid, and hypoxia) that
individually elicit the discrete phenotypes of MGL1
/
CD11c
 and MGL1
/CD11c
 eATMs, respectively.
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FIG. 3. Prolonged (12-week) HFD feeding promotes M2-associated gene expression differentially in MGL1-expressing and CD11c-expressing
eATMs. mRNA levels of inﬂammation-, metabolism-, remodeling-, and antigen presentation–related genes were analyzed by quantitative PCR
after 12 weeks of HFD in each eATM subtype (supplemental Fig. 3). mRNA levels were compared with levels determined after 8 weeks of HFD
(set as “1” and indicated by the horizontal line). Data for each eATM subtype are from 6 mice (week 8) and 9–11 mice (week 12), respectively.
*P < 0.05; **P < 0.01, ANOVA and Tukey procedure.
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tional modulation in each of the three eATM subtypes
(Fig. 3). MGL1-expressing eATMs upregulated hallmark
M2 genes and downregulated iNOS (Fig. 3). The MGL1
med/
CD11c
 subtype additionally upregulated MMP-2, CD163,
and LYVE-1 (Fig. 3) and was three times more likely than
other eATM subtypes to stain for the IB4 isolectin (data
not shown), a marker of adipogenic and angiogenic activ-
ities in eAT of obese mice (14). The increases in LYVE-1
and MMP-2 mRNAs are intriguing in light of proposed role
of LYVE-1
 eATMs in new vessel development during
eAT expansion (19), and the demonstration that MMP-2 is
required for diet-induced adipocyte hypertrophy (26).
These observations are consistent with the localization of
MGL1
med/CD11c
 eATMs to remodeling clusters (Fig. 2)
and suggest a functional role in angiogenesis and/or
adipogenesis.
An unexpected feature of CD11c
 eATM gene expres-
sion at HFD week 12 was the robust upregulation of
PGC-1 (Fig. 3) (rev. in 34). Although little is known
concerning the role of PGC-1 in M polarization (35), its
role in promoting mitochondrial biogenesis and oxidative
metabolism suggests that, similar to PGC-1 (28), PGC-
1–mediated gene expression promotes/maintains the M2
state. MGL1
med/CD11c
 eATMs additionally expressed
high levels of PPAR- mRNA, suggesting increased fatty
acid metabolism and blunted proinﬂammatory responses
to Th1 cytokines (36). At HFD week 12, both CD11c

eATM subtypes expressed reduced levels of M1-associ-
ated transcripts (iNOS, IL-1, I-a, and CD80) as well as
ARG-1 mRNA. These reductions suggest a relatively deac-
tivated M2c phenotype, consistent with the elevated IL-10
gene expression observed in eAT at this time (Fig. 5) (12).
Similar downregulation of M1 cytokines, iNOS and ARG-1
is observed in M2c-polarized Ms during the reparative
phase of murine muscular dystrophy (37).
Systemic PPAR- activation by thiazolidinediones
(TZDs) promotes ATM recruitment, M2-associated gene
expression, and tissue remodeling in eAT of obese rodents
(29,30,38,39). Surprisingly, acute (1-week) exposure to
TZDs also increases CD11c mRNA in eAT (38) (Fig. 4). The
seemingly anomalous observation of increased CD11c
gene expression in response to M2-polarizing treatment is
explained by our demonstration that MGL1
med/CD11c

TABLE 3
Fold difference in mRNA levels of genes regulating inﬂammation, metabolism, tissue remodeling, and antigen presentation in eATM
subtypes after 12 weeks of HFD relative to benchmark M2-polarized MGL1
/CD11c
 eATMs from mice fed an LFD for 8 weeks
8 weeks LFD 12 weeks HFD
MGL1
 CD11c

MGL1

CD11c

MGL1
med
CD11c

MGL1

CD11c

Pro-/anti- Inﬂammatory markers
Gene
IL-13 * 8.15  3.09† 2.08  0.66* 0.15  0.11‡
Ym-1 * 7.98  2.16† 1.04  0.18* 0.68  0.17*
STAT6 * 5.24  1.78† 1.51  0.25* 0.86  0.20*
SPHK1 * 0.52  0.08† 0.41  0.05† 0.22  0.02‡
IL-10 * 1.32  0.11† 0.62  0.12‡ 0.75  0.20*‡
IL-1Ra * 2.94  0.35† 8.47  1.56‡ 7.40  1.01‡
CD163 * 0.28  0.01† 0.13  0.006‡ 0.02  0.005‡
CD206 * 0.57  0.12† 0.38  0.03† 0.22  0.02‡
Clec-7a * 1.05  0.18* 1.36  0.20*† 1.84  0.19†
IL-1 * 1.15  0.12* 0.95  0.17* 1.99  0.21†
Caspase-1 * 0.57  0.04* 0.54  0.05* 0.52  0.05*
IL-12p40 * 4.85  1.24† 6.80  1.61† 11.4  3.53†
TLR-4 * 0.91  0.09* 0.89  0.09* 0.56  0.05†
MCP-1 * 0.37  0.10† 0.21  0.02† 0.03  0.004‡
Metabolism
Genes
ARG-1 * 0.70  0.13* 0.93  0.17* 0.98  0.12*
iNOS * 0.53  0.25* 0.09  0.01† 0.03  0.01‡
PGC-1 * 43.7  13.6† 283.4  88.5‡ 107.8  24.2‡
PGC-1 * 0.56  0.07† 0.56  0.13† 0.53  0.14†
ADRP * 1.75  0.14† 2.26  0.30† 2.24  0.26†
Remodeling
Genes
MMP-2 * 4.95  0.91† 6.39  1.90† 1.66  0.48*
MMP-12 * 40.7  10.3† 360  55‡ 292  46‡
TGF-1 * 2.43  0.35† 2.36  0.49† 2.41  0.42†
VEGF * 2.48  0.17† 5.48  1.17‡ 8.95  2.53‡
ADAM-8 * 6.18  0.38† 14.28  0.82‡ 14.57  0.77‡
LYVE-1 * 0.42  0.15† 0.26  0.08† 0.005  0.001‡
Antigen presentation
Genes
I-a *‡ 0.71  0.08* 0.46  0.08† 0.99  0.07‡
CD80 * 0.37  0.04† 0.26  0.04‡ 0.18  0.04‡
CD86 * 0.48  0.05† 0.17  0.03‡ 0.10  0.02‡
Data are means  SE. Means designated by different symbols are signiﬁcantly different (P  0.05, ANOVA and Tukey procedure).
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the TZD PIO, a PPAR-/- agonist (40). MGL1
med/CD11c

eATMs in mice fed HFDPIO upregulated the M2-
associated transcripts Ym-1, PGC-1, and PPAR- (Fig. 4)
similar to MGL1
med/CD11c
 eATMs in mice fed an HFD
for 12 weeks (Fig. 3 and supplemental Fig. 4). These
observations support the notion that MGL1
med/CD11c

eATMs become more M2 polarized at HFD week 12 and
suggest that PPAR- (and/or PPAR-) activation by endog-
enous ligands contributes to this polarization.
TZDs promote insulin sensitivity, in part, by promoting
fat oxidation and the remodeling of adipose tissue with
additional, small adipocytes (29,39,41,42). Our data sug-
gest that these actions may be promoted in eAT with
minimal inﬂammatory impact by the selective recruitment
of MGL1
med/CD11c
 eATMs expressing high levels of
IL-13, PGC-1, MMP-2, and LYVE-1 and relatively reduced
levels of IL-1 and IL-12p40 as compared with MGL1
/
CD11c
 eATMs (Table 3). However, the whole-body
insulin-sensitizing effects of PIO also reﬂect its beneﬁcial
actions in multiple cells and tissues, including subcutane-
ous adipose tissue (39,41,42). Thus, despite increases in
MGL1
med/CD11c
 at HFD week 12, increased insulin re-
sistance (Table 1) is not totally unexpected at this time
given the coincident increase in MGL1
/CD11c
 eATMs
(Fig. 1D) in the absence of the pleiotropic ameliorative
actions of PIO.
In closing, we note that the mixed M1/M2 eATM
phenotypes described above were associated with pro-
gressively increasing and coordinate expression of M1 and
M2/remodeling genes in whole eAT (Fig. 5). Multiple eAT
cell types, in addition to eATMs, undoubtedly contribute
to this mixed inﬂammatory proﬁle. Nevertheless, our data
demonstrate that HFD-induced whole-body insulin resis-
tance (Table 1) develops in this model coincident with
both an M2 as well as an M1 progression in eAT. This
conclusion may reﬂect our use of a 60% (kcal) HFD,
containing 33% more energy from fat than the diet used by
Lumeng and colleagues (10,11) to elucidate the M1
eATM switch. Although qualitatively identical, the higher
fat content may promote more eAT remodeling and may
coincidentally attenuate M proinﬂammatory signaling
(43). In particular, lipid scavenging by CD11c
 eATMsa t
sites of adipocyte death (7) may render them particularly
prone to the M1-inhibiting and/or M2-promoting effects of
particular fatty acids (43,44). Future studies will address
mechanisms by which dietary fat and/or adipose tissue
microenvironments shape ATM polarization and its in-
ﬂammatory and metabolic sequelae.
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